Health Care & Life Sciences » Pharmaceuticals | Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
24,967.00
20,651.00
2,263.20
5,589.80
13,949.70
1,556.70
Depreciation, Depletion & Amortization
1,124.00
774.00
5,712.40
1,485.20
1,255.20
1,073.20
Other Funds
509.00
1,308.00
42.20
5,074.50
11,745.70
3,128.90
Funds from Operations
20,044.00
22,403.00
4,218.10
14,126.30
31,174.30
7,395.80
Changes in Working Capital
12,569.00
4,930.00
3,143.40
4,414.60
8,386.40
6,343.30
Net Operating Cash Flow
7,475.00
27,333.00
1,074.70
18,541.00
22,787.90
13,739.20
Capital Expenditures
15.00
903.00
9,678.50
144.40
262.20
Sale of Fixed Assets & Businesses
-
-
-
-
12,122.10
Net Investing Cash Flow
15.00
903.00
67,686.70
9,705.10
2,592.10
Issuance/Reduction of Debt, Net
-
-
51,175.00
42.40
34,323.30
Net Financing Cash Flow
876.00
2,022.00
52,362.30
828.10
33,440.60
Net Change in Cash
8,336.00
28,452.00
23,266.70
9,677.20
8,106.10
Free Cash Flow
7,460.00
27,315.00
855.90
18,495.90
22,717.80
Deferred Taxes & Investment Tax Credit
6,556.00
330.00
3,715.30
1,976.80
4,223.70
1,637
Net Assets from Acquisitions
-
-
58,008.20
-
-
Change in Capital Stock
876.00
2,022.00
1,187.30
870.50
882.60
Exchange Rate Effect
-
-
9,017.00
13.20
45.40
Other Uses
-
-
-
9,560.60
9,267.80

About Cipher Pharmaceuticals

View Profile
Address
209 Oak Park Boulevard
Oakville Ontario L6H 0M2
Canada
Employees -
Website http://www.cipherpharma.com
Updated 07/08/2019
Cipher Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the robust and diversified portfolio of commercial and late-stage products. It also acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly or through partners. Its products include Actikerall, Aclaro, Beteflam, Epuris, Vaniqa, Dermadexin, Pruridexin, Ozenoxacin, Lipofen, Conzip, and Durela.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.